Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We ...

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...